TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9662077
Drug: Duodenal lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal lipid (Intralipid 20%) infusion for 15 minutes
Study: 20125186
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (CC)
Study: 22155561
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 30 mg
Study: 11570305
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy with low-dose acetylsalicylic acid (ASA) initiated within 48 hours of stroke onset
Study: 8323207
Drug: Traditional graduated
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional graduated regimen of 30 ml/h for 24 h, 60 ml/h for 24 h, 90 ml/h for 24 h, then free fluids (group 2)
Study: 25452452
Drug: Nivolumab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 0.3 mg/kg
Study: 26861469
Drug: Nivolumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 2.0 mg/kg
Study: 26861469
Drug: Nivolumab 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 10.0 mg/kg
Study: 26861469
Drug: Nivolumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (all doses)
Study: 22434968
Drug: Yoga exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga exercise for 50 minutes daily for 4 weeks
Study: 15925132
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for body image concerns
Study: 2030191
Drug: Preparation stage
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation stage
Study: 7102445
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stages
Study: 19478198
Drug: Saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 2.5 mg plus metformin
Study: 19478198
Drug: Saxagliptin (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin (2.5, 5, and 10 mg) plus metformin
Study: 24565221
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus metformin
Study: 17192326
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy (infrared skin thermometer to measure temperatures on six foot sites daily)
Study: 9725760
Drug: IV ASA
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ASA medication
Study: 25354720
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid combined with androgen-deprivation therapy.
Study: 24643488
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment intervention
Study: 21983612
Drug: Toothpastes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpastes with natural compounds
Study: 31142357
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy
Study: 11384687
Drug: Vasopressin 10
Normalized name: VASOPRESSIN 10UNT/0.5ML INJ,VIL,0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin 10 units/10 mL of normal saline
Study: 23188121
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg
Study: 21939510
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid for two weeks
Study: 24075764
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg/day
Study: 18312764
Drug: fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluvastatin XL 80 mg/day plus ezetimibe 10 mg/day
Study: 16361021
Drug: Dexanabinol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexanabinol (150 mg intravenous dose within 6 hours of injury)
Study: 12540407
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (subgroup >6 years postmenopause)
Study: 8874308
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (0.02 mg/kg)
Study: 8874308
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (0.2 mg/kg)
Study: 6430605
Drug: Mestranol 24
Normalized name: Mestranol
DrugBank: Mestranol (DB01357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mestranol 24 micrograms daily
Study: 25268962
Drug: Current PPI
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current PPI use among patients receiving diuretics
Study: 25268962
Drug: Current PPI
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current PPI use among patients not receiving diuretics
Study: 25268962
Drug: Histamine H2
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H2 receptor antagonists
Study: 16488958
Drug: Combined photodynamic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined photodynamic therapy (PDT) with intravitreal triamcinolone (IVTA)
Study: 16488958
Drug: PDT monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT monotherapy
Study: 15692919
Drug: Renal doses
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Renal doses of dopamine in the postoperative period
Study: 15692919
Drug: Renal doses
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Renal doses of dopamine in the preoperative period
Study: 7763202
Drug: Acetylcysteine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (50 mg/kg per day subcutaneously for 12 months)
Study: 438014
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of dry air at various temperatures (subzero to 80 degrees C) during exercise
Study: 438014
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of dry air at temperatures above 37 degrees C
Study: 30554925
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine periarticular injection (PAI)
Study: 3746543
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone (control group)
Study: 25463545
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus albumin
Study: 21327673
Drug: Propiverine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine ER 30 mg o.d. as add-on to α-blockers (CT)
Study: 21327673
Drug: Propiverine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine ER 30 mg o.d. as monotherapy (MT)
Study: 19617815
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) treatment with antiretroviral therapy (nucleoside analogues) for 12 months
Study: 19617815
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy alone for 12 months
Study: 19617815
Drug: IL-2 experienced
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 experienced adults on highly active antiretroviral therapy
Study: 15740555
Drug: EC‐MPS 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 640 mg
Study: 15740555
Drug: EC‐MPS 720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 720 mg
Study: 15740555
Drug: MMF 1000
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1000 mg
Study: 10524663
Drug: Acetaminophen, aspirin,
Normalized name: Acetaminophen, Aspirin, and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, aspirin, and caffeine (AAC)
Study: 1820903
Drug: New Levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Levothyroxine solution
Study: 1820903
Drug: Reference L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference L-thyroxine solution
Study: 3887851
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g daily)
Study: 7042486
Drug: Caved-S (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caved-S (six tablets daily)
Study: 12154424
Drug: Bronchial blocker
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial blocker (BB) with single-lumen tube (SLT)
Study: 7658498
Drug: Tamoxifen (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (specific dosage and duration not mentioned)
Study: 10511361
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate
Study: 26535958
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioral therapy (wCBT)
Study: 7508828
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg
Study: 9669812
Drug: Fluconazole in
Normalized name: fluconazole Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole in addition to standard prophylaxis (oral co‐trimoxazol, colistin sulphate, and amphotericin B suspension)
Study: 9669812
Drug: Standard prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylaxis only (oral co‐trimoxazol, colistin sulphate, and amphotericin B suspension)
Study: 27859599
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral immunotherapy (OIT)
Study: 30447012
Drug: Online serious
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online serious game for dental treatment preparation
Study: 19114188
Drug: Moderate-potassium adenosine-lidocaine
Normalized name: alum, potassium / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-potassium adenosine-lidocaine (MPAL) group (K(+), 10 mmol/L; adenosine, 0.7 mmol/L; lidocaine, 0.7 mmol/L)
Study: 19114188
Drug: High-potassium adenosine-lidocaine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-potassium adenosine-lidocaine (HPAL) group (K(+), 20 mmol/L; adenosine, 0.7 mmol/L; lidocaine, 0.7 mmol/L)
Study: 16543907
Drug: GW660511X 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW660511X 200 mg
Study: 12941708
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg daily for 3 months)
Study: 8653990
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg tablet)
Study: 2903817
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg twice daily)
Study: 6374681
Drug: Trazodone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone administered as divided doses twice daily
Study: 6374681
Drug: Trazodone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone administered as a single dose at night
Study: 6374681
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (single dose at night and divided doses)
Study: 9731006
Drug: Theophylline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (mean serum level: 9.9 +/- 1.1 mg/L, Days 1 to 40) + inhaled salmeterol (50 microgram twice daily, Days 8 to 36)
Study: 8067245
Drug: Oxymetazoline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline administered with a nasal bellows (OXBE)
Study: 8067245
Drug: Oxymetazoline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline with conventional nasal spray (OXSP)
Study: 8067245
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (PLSP)
Study: 27325390
Drug: G‐Pump glucagon
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Pump glucagon 1.2 µg/kg
Study: 27325390
Drug: GlucaGen 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlucaGen 2.0 µg/kg
Study: 27325390
Drug: G‐Pump glucagon
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Pump glucagon
Study: 24534400
Drug: Nebulized beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized beclomethasone 400 μg twice daily for 10 days
Study: 24534400
Drug: Nebulized beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized beclomethasone 400 μg
Study: 25943350
Drug: Postoperative docetaxel-5FU
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative docetaxel-5FU regimen (D 85 mg/m2, day 1 and 5FU 750 mg/m2/day continuous infusion, days 1-5 every 3 weeks) after preoperative dose-intense epirubicin-cyclophosphamide (E 150 mg/m2 and C 4000 mg/m2 every 3 weeks) and locoregional treatment.
Study: 25943350
Drug: Preoperative dose-intense
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative dose-intense epirubicin-cyclophosphamide (E 150 mg/m2 and C 4000 mg/m2 every 3 weeks) followed by mastectomy and radiotherapy.
Study: 22266683
Drug: Footrot vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Footrot vaccine (Footvax, MSD) plus targeted antibiotic therapy (long‐acting amoxicillin, Betamox LA, Norbrook Pharmaceuticals)
Study: 22266683
Drug: Targeted antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotic therapy only
Study: 7630674
Drug: Prednisone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (2 mg/kg up to 60 mg)
Study: 17049710
Drug: Biological threat
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological threat stimuli (CS-) not directed towards participants
Study: 23748117
Drug: Naloxone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (8 mg)
Study: 26340920
Drug: Alcohol group
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol group (0.7 g/kg)
Study: 17028353
Drug: sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual misoprostol 50 micrograms every 4 hours for up to five doses
Study: 20724487
Drug: Smoothie containing
Normalized name: CONTAINER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoothie containing 22.5 g blueberry bioactives
Study: 16088807
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine (3 concentrations: 10(4.7), 10(5.2), 10(6.1) focus-forming units)
Study: 11248824
Drug: Ciprofloxacin 0.3%
Normalized name: Ciprofloxacin 0.3%, Fluocinolone Acetonide 0.025% Otic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 0.3% ophthalmic solution
Study: 1928272
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (fortified cefazolin 33 mg/ml and fortified gentamicin or tobramycin 14 mg/ml)
Study: 29037631
Drug: Bowen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowen Therapy
Study: 26502357
Drug: TAK-385 (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 (0 [placebo], 80, 120, 180, or 360 mg) single doses
Study: 26502357
Drug: TAK-385 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 (40 [with loading dose], 60, 80, or 160 mg) daily for 28 days
Study: 26502357
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of TAK‐385 on day 28
Study: 26502357
Drug: TAK-385 (40-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 (40-180 mg/d)
Study: 22383508
Drug: Oral ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ascorbic acid (Asc) 2-g single dose
Study: 10761170
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg daily for 12 weeks
Study: 8158539
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (300 mg monthly)
Study: 8158539
Drug: Low-dose daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daily TMP-SMX (400-80 mg)
Study: 10663358
Drug: HRT (piperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (piperazine estrone sulfate 0.625‐0.937 mg daily +/‐ medroxyprogesterone acetate 2.5 mg daily)
Study: 14633812
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg/day)
Study: 12756490
Drug: Selenium and
Normalized name: Selenium and/or selenium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium and Vitamin E combination
Study: 18090872
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy (conjugated equine estrogens: 0.625 mg/d)
Study: 6340552
Drug: Enprofylline 2
Normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 2 mg/kg b.wt.
Study: 6340552
Drug: Enprofylline 4
Normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 4 mg/kg b.wt.
Study: 29417793
Drug: Oral supplement
Normalized name: Healios Oral Supplement Unflavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement (biotin, probiotic, vitamin E, zinc, nicotinamide; males: beta sitosterol and Boswellia serrata; females: myo‐inositol and folic acid) and topical cream device (verbascoside, Ocimum gratissimum, salicylic acid, gluconolactone, complex alpha‐hydroxy acids)
Study: 29417793
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream device (verbascoside, Ocimum gratissimum, salicylic acid, gluconolactone, complex alpha‐hydroxy acids)
Study: 29417793
Drug: Oral supplement
Normalized name: Healios Oral Supplement Unflavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement
Study: 25856160
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (0.45 mg/day) with intermittent progesterone (200 mg/day for 12 days a month)
Study: 25856160
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (50 µg/day) with intermittent progesterone (200 mg/day for 12 days a month)
Study: 26508701
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills and patch
Study: 25367551
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg/kg + normal saline 0.05 ml/kg (KET)
Study: 25367551
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg/kg + dexmedetomidine 0.5 μg/kg (KETODEX)
Study: 25367551
Drug: Placebo (volume-matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (volume-matched normal saline 0.15 mL/kg + normal saline 0.05 mL/kg)
Study: 20500877
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg metoprolol succinate
Study: 10821991
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg carvedilol
Study: 15950631
Drug: Utrogest 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogest 200 (200 mg vaginal capsules, three times per day)
Study: 15950631
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% (vaginal gel, two times per day)
Study: 11474769
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs (AEDs) such as oxcarbazepine, levetiracetam, zonisamide, lamotrigine, and topiramate
Study: 9578541
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs (AEDs)
Study: 11474769
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of new AEDs
Study: 11474769
Drug: First therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First therapy given to newly diagnosed patients
Study: 8306268
Drug: IMMU-4 99mTc-Fab'
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMMU-4 99mTc-Fab' fragments (1 mg, 19.3 mCi average)
Study: 2471472
Drug: Trimethoprim (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (200 mg with procainamide dose after 100 mg twice a day for 2 days)
Study: 377448
Drug: Ketoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200 mg/day)
Study: 28091641
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog therapy with pomegranate extract
Study: 21829006
Drug: IM peribulbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM peribulbar injection
Study: 20014598
Drug: Ropivacaine 19.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 19.5 mg with fentanyl 20 microg (group R)
Study: 20014598
Drug: Bupivacaine 13
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 13 mg with fentanyl 20 microg (group B)
Study: 15638236
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) administered as three infusions at 0, 2, and 6 weeks, then every 8 weeks
Study: 15638236
Drug: Methylprednisolone (0.7-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (0.7-1 mg/kg) daily for one week followed by tapering regimen
Study: 11442865
Drug: Caudal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal tramadol 2 mg.kg‐1 (group T)
Study: 11442865
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine 0.03 mg.kg‐1 (group M)